Pre-clinical mechanism
Thymosin β-4 binds G-actin and modulates cytoskeletal dynamics, with downstream effects on cell migration, angiogenesis, and inflammatory cytokine expression in pre-clinical wound models. The N-terminal LKKTETQ fragment (TB-500) retains a portion of these activities in vitro.
Key pre-clinical findings
- Cardiac infarct rodent model: reduced scar volume and improved ejection fraction in mouse MI studies (Bock-Marquette et al., 2004).
- Dermal wound healing: faster re-epithelialisation in full-thickness rodent wounds (Malinda et al., 1999).
- Corneal epithelial defect models: accelerated closure and reduced inflammatory infiltrate (Sosne et al., 2002).
Primary literature
Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Bock-Marquette I, Saxena A, White MD, et al. · Nature · 2004
Thymosin beta 4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology · 1999
Thymosin beta 4 promotes corneal wound healing and decreases inflammation
Sosne G, Szliter EA, Barrett R, et al. · Experimental Eye Research · 2002
Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.